Method of evaluating adrenal steroids in saliva collected by cotton swab
11360105 · 2022-06-14
Assignee
Inventors
Cpc classification
G01N2560/00
PHYSICS
International classification
Abstract
The present invention relates to a method for evaluating metabolic activity based on the concentrations of cortisol and its precursors and metabolites thereof in saliva collected by a swab for the measurement of adrenal steroids relating to biochemical stress evaluation and more particularly, to a method of comparing metabolic activity of physiologically different adrenal steroids by analyzing adrenal steroids including cortisol and cortisone extracted from a trace amount of saliva by mass spectrometry and evaluating the metabolic ratio between the two compounds as well as the absolute amount of each compound. Accordingly, the present invention can be utilized as an index for evaluating response to biochemical stress and related diseases by measuring the amounts of adrenal steroids including cortisol and cortisone in a trace amount of saliva collected with a swab.
Claims
1. A method for quantitatively analyzing (assaying) adrenal steroids in saliva, comprising: (a) collecting saliva using a saliva adsorption material; (b) enzymatic hydrolysis of the saliva; (c) extracting the hydrolyzed saliva by elution through a solid-phase extraction method using a C.sub.1 to C.sub.5 alcohol solvent; and (d) re-dissolving the extracted sample in an organic solvent and analyzing the resulting sample by liquid chromatography-mass spectrometry, wherein the ionization method of analysis by liquid chromatography-mass spectrometry in step (d) is electrospray ionization (ESI), wherein a flow rate of nitrogen spray gas used for electrospray ionization is from 2.0 L/min to 3.0 L/min, a vaporization temperature is from 250 to 350° C. and a capillary voltage is from 3.0 kV to 5.0 kV.
2. The method according to claim 1, wherein the saliva adsorption material is a cotton swab.
3. The method according to claim 1, wherein the C.sub.1 to C.sub.5 alcohol solvent is a selected from methanol solvent, ethanol solvent, propanol solvent, butanol solvent and pentanol solvent.
4. The method according to claim 1, wherein the step of collecting saliva comprises allowing the saliva adsorption material to retain in the mouth for 1 minute or less.
5. The method according to claim 4, further comprising mixing the saliva adsorption material soaking the saliva in step (a) with internal standards of adrenal steroid to be analyzed before hydrolysis.
6. The method according to claim 1, wherein the enzymatic hydrolysis of step (b) is carried out using β-glucuronidase.
7. The method according to claim 1, wherein a column of the liquid chromatography of step (d) has a length of 40 to 60 mm, an inner diameter of 1 to 3 mm and a filler particle size of 1.0 μm to 3.0 μm.
8. The method according to claim 1, wherein a mobile phase of the liquid chromatography of step (d) has a concentration gradient of an aqueous solution (A) containing 5% acetonitrile and 0.1% formic acid, and a 95% acetonitrile aqueous solution (B) containing 0.1% formic acid, and a flow rate is maintained at 0.20 mL/min to 0.30 mL/min.
9. The method according to claim 8, wherein a concentration gradient condition of liquid chromatography of step (d) is set such that, from A:B=90:10 (v/v), B is adjusted to 25% at 5 minutes, B is adjusted to 60% at 8 minutes, B is adjusted to 100% at 14 minutes, B is returned to 10% of the initial composition at 18 minutes, and B is maintained at 10% for 10 minutes.
10. The method according to claim 5, wherein the internal standards comprise deuterium-substituted progesterone for progesterone, and deuterium-substituted cortisol for cortisol, cortisone, and precursors and metabolites of cortisol.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The above and other features of the present invention will now be described in detail with reference to certain exemplary embodiments thereof illustrated in the accompanying drawings which are given hereinbelow by way of illustration only, and thus are not limitative of the present invention, and wherein:
(2)
(3)
DETAILED DESCRIPTION
(4) Unless context clearly indicates otherwise, all numbers, figures and/or expressions that represent ingredients, reaction conditions, polymer compositions and amounts of mixtures used in the specification are approximations that reflect various uncertainties of measurement occurring inherently in obtaining these figures among other things. For this reason, it should be understood that, in all cases, the term “about” modifies all the numbers, figures and/or expressions. In addition, when numerical ranges are disclosed in the description, these numerical ranges are continuous and include all numbers from the minimum to the maximum including the maximum within the ranges unless otherwise defined. Furthermore, when the range is referred to as an integer, it includes all integers from the minimum to the maximum including the maximum within the range, unless otherwise defined.
(5) It should be understood that, in the specification, when the range is referred to regarding a parameter, the parameter encompasses all figures including end points disclosed within the range. For example, the range of “5 to 10” includes figures of 5, 6, 7, 8, 9, and 10, as well as arbitrary sub-ranges such as ranges of 6 to 10, 7 to 10, 6 to 9, and 7 to 9, and any figures, such as 5.5, 6.5, 7.5, 5.5 to 8.5 and 6.5 to 9, between appropriate integers that fall within the range. In addition, for example, the range of “10% to 30%” encompasses all integers that include figures such as 10%, 11%, 12% and 13%, as well as 30%, and any sub-ranges of 10% to 15%, 12% to 18%, or 20% to 30%, as well as any figures, such as 10.5%, 15.5% and 25.5%, between appropriate integers that fall within the range.
(6) Hereinafter, the present invention will be described in detail.
(7) The present invention includes collecting a trace amount of saliva using a cotton swab, hydrolyzing and extracting salivary adrenal steroids including cortisol and cortisone with an enzyme and then removing analytical interfering substances through solid-phase extraction and at the same time, purifying and concentrating the compounds to be analyzed. The present invention includes measuring the absolute amount of adrenal steroids by chromatographic separation combined with mass spectrometric detection and evaluating the metabolic ratio therebetween.
(8) The present invention includes extracting the saliva using a cotton swab, extracting adrenal steroids including cortisol and cortisone from the saliva soaked in the cotton swab, purifying and concentrating the resulting extract through a solid-phase extraction method, re-dissolving the resulting product in an organic solvent, determining the concentration of the compounds by liquid chromatography-mass spectrometry, and determining the metabolic ratio between cortisol and cortisone.
(9) Various aspects of the present invention are described below.
(10) In one aspect of the present invention, there is provided a method for quantitatively analyzing (assaying) adrenocortical hormones in saliva, including (a) collecting saliva using a saliva adsorption material (cotton swab), (b) enzymatic hydrolysis of the salivary adrenal steroids, (c) extracting the hydrolyzed saliva by elution through a solid-phase extraction method using a C.sub.1 to C.sub.5 alcohol solvent (methanol solvent), and (d) re-dissolving the extracted sample in an organic solvent and analyzing the resulting sample by liquid chromatography-mass spectrometry.
(11) The term “salivary adrenal steroids” means at least one selected from six types of hormones illustrated in
(12) In one embodiment, the saliva sample of step (a) may be obtained from any subject such as a healthy subject (hereinafter, the same will apply), a subject having a disease, or a subject in need of diagnosis of disease contraction.
(13) In one aspect of the present invention, the step of collecting saliva includes allowing the cotton swab to retain in the mouth for 1 minute or less, preferably 3 to 5 seconds.
(14) In one aspect of the present invention, the method includes mixing the cotton swab soaking the saliva in step (a) with an internal standard substance of the adrenal steroid to be analyzed before hydrolysis.
(15) In one aspect of the present invention, the enzymatic hydrolysis of step (b) is carried out using β-glucuronidase.
(16) In one aspect of the present invention, the ionization method of analysis by liquid chromatography-mass spectrometry in step (d) is electrospray ionization (ESI).
(17) In one aspect of the present invention, the flow rate of the nitrogen spray gas used for the electrospray ionization is from 2.0 L/min to 3.0 L/min, the vaporization temperature is from 250 to 350° C., and the capillary voltage is from 3.0 kV to 5.0 kV.
(18) In one aspect of the present invention, the column of the liquid chromatography of step (d) has a length of 40 to 60 mm, an inner diameter of 1 to 3 mm and a filler particle size of 1.0 m to 3.0 m.
(19) In one aspect of the present invention, the mobile phase of the liquid chromatography of step (d) has a concentration gradient of an aqueous solution (A) containing 5% acetonitrile and 0.1% formic acid, and a 95% acetonitrile aqueous solution (B) containing 0.1% formic acid, and the flow rate is maintained at 0.20 ml/min to 0.30 ml/min.
(20) In one aspect of the present invention, the concentration gradient condition of liquid chromatography of step (d) is set such that, from A:B=90:10 (v/v), B is adjusted to 25% at 5 minutes, B is adjusted to 60% at 8 minutes, B is adjusted to 100% at 14 minutes, B is returned to 10% of the initial composition at 18 minutes, and B is maintained at 10% for 10 minutes.
(21) In one aspect of the present invention, the internal standards include deuterium-substituted progesterone (progesterone-2,2,4,6,6,17a,21,21,21-d.sub.9) for progesterone, and deuterium-substituted cortisol (cortisol-9,11,12,12-d.sub.4) for cortisol, cortisone and metabolites of cortisol.
(22) Hereinafter, the present invention will be described in more detail with reference to specific examples. These examples are provided only for illustration to aid in understanding of the present invention and should not be construed as limiting the scope of the present invention.
Example 1
(23) 1) Saliva Collection
(24) A cotton swab generally used for household and medical use was put in the saliva around the tongue of the mouth, or soaked therein for about 3-5 seconds, and then stored in a 1.5 mL microtube or a test tube with a stopper in the freezer until the experiment. For the experiment, the swab in the tube was transferred to the test tube and 20 μL of a deuterium-substituted internal standard mixture solution (d.sub.4-cortisol, d.sub.9-progesterone) was added thereto.
(25) 2) Enzymatic Hydrolysis
(26) 1.5 mL of phosphate buffer (pH 7.2) was added to the test tube, shaken for 5 seconds, 50 μl of β-glucuronidase was added thereto and reacted at 55° C. for 1 hour. The reaction solution was allowed to cool at room temperature.
(27) 3) Solid-Phase Extraction Method
(28) An Oasis HLB cartridge (60 mg/3 cc, Waters, Milford, Mass., USA) was used for solid phase extraction. 2 mL of methanol and water were each allowed to flow into the cartridge twice and a swab was injected into the cartridge with a pair of tweezers. The analytes, adrenocortical hormones containing cortisol and cortisone were allowed to remain in the stationary phase by flowing the extract of 2) above. The resulting steroids were washed with a total of twice with 0.7 mL of 10% methanol in order to remove the matrix components in the saliva remaining in the stationary phase. Finally, 1 mL of methanol was allowed to flow a total of twice to obtain an eluent of the analyte in a clean test tube. Thereafter, the solvent contained in the eluent was removed at 40° C. using a nitrogen evaporator.
(29) 4) Liquid Chromatography-Mass Spectrometry
(30) 50 μL of methanol was added to the dried residue of step 3), mixed for 30 seconds and filtered at 14,000 rpm in an Ultrafree®-MC VV centrifugal filter (0.1 μm filter unit; Millipore, Bedford, Mass., USA) for 5 minutes. Then, 50 μL of 10% DMSO was added to the test tube, mixed for 30 seconds and then filtered through the same filter as above at 14,000 rpm for 5 minutes. The filtered sample was injected into a liquid chromatography vial and analyzed for an injection amount of 5 μL.
(31) The liquid chromatograph-mass spectrometer used in the analysis is a Nexera ultrahigh performance liquid chromatography system with a LCMS-8050 triple quadrupole mass spectrometer produced by Shimadzu. The ionization method of the mass spectrometer was electrospray ionization (ESI) and uses multiple-reaction monitoring (MRM). In addition, the column used for the analysis was a Hypersil GOLD C18 produced by Thermo Fisher. The column had a length of 50 mm, an inner diameter of 2 mm and a filler particle size of 1.9 μm. The mobile phases used herein included an aqueous solution (A) containing 5% acetonitrile and 0.1% formic acid and 95% acetonitrile (B) containing 0.1% formic acid. At this time, the flow rate was 0.25 mL/min. The conditions of the gradient elution method were as follows: initially setting B to 10%, setting B to 25% at 5 minutes, setting B to 30% at 8 minutes, setting B to 60% at 10 minutes, setting B to 100% at 14 minutes, setting B to 10% of the initial composition at 18 minutes, and maintaining B at 10% for 10 minutes. The flow rate of the nitrogen spray gas used for the electrospray ionization method was 2.5 L/min, the gasification temperature was 300° C. and the capillary voltage was 4.0 kV.
(32) Adrenal steroids including cortisol and cortisone were assayed on the basis of their respective internal standards and were qualitatively identified by comparing the height ratio of two characteristic ion peaks per compound and the retention time in the column.
(33) 5) Evaluation of Concentration of Analyte Compounds
(34) In order to evaluate the amounts of adrenal steroids including cortisol and cortisone in the saliva collected from the swab, a standard solution of each compound was taken at each concentration and a sample for the quantitative curve was prepared. Then, a calibration curve was made, based on the ratio of the peak height of each compound to the peak height of the internal standard, obtained by treatment in the same manner as in an actual clinical sample in accordance with the description of 1), 2), 3), 4) above. The absolute amount of adrenocortical hormones was measured by applying the ratio of the compound detected from the sample to the equation of “y=ax+b” obtained based on the prepared calibration curve.
(35) In addition, the amount of saliva collected in the swab used in the experiment could not be accurately calculated, and as the size of the swab increases, the amount of collected saliva increases. For this reason, the metabolic ratio between the compounds can be calculated based on the absolute amount of the measured compounds. The metabolic ratio (F/E) of cortisol (F) to cortisone (E) was determined to evaluate the activity of 11β-HSD.
Test Example 1
(36) The absolute amount of cortisol and cortisone was measured using saliva soaked in swabs collected from six pituitary Cushing's disease patients and ten healthy subjects through the analytical method of Example 1 and then was compared with the case of 0.2 mL of saliva samples obtained from the same subjects using a kit (Salivette® Cortisol; Sarstedt, Nümbrecht, Germany), which had been conventionally mainly used in the clinical practice. In particular, the metabolic ratios therebetween were measured to evaluate the activity of 11β-HSD. Results are shown in Table 1.
(37) The amounts of assayed cortisol and cortisone of the Cushing's disease patient group were 10 times and 3 times higher than those of the healthy group, respectively, and the corresponding results were similar in both conventional kit-using and swab-using methods.
(38) TABLE-US-00001 TABLE 1 Patients with Healthy subjects Cushing's disease Conventional Conventional saliva kit Swab saliva kit Swab Analyte (ng/mL) (pg) (ng/mL) (pg) Cortisol (F) 3.87 ± 1.62 584 ± 125 31.11 ± 16.14 5378 ± 1208 Cortisone (E) 12.32 ± 4.93 1029 ± 367 31.83 ± 16.66 3247 ± 644 F/E 0.36 ± 0.18 1.93 ± 4.09 0.51 ± 0.74 0.66 ± 1.08
Test Example 2
(39) The absolute amounts of adrenal steroid including cortisol and cortisone in saliva collected from swabs could be evaluated. The salivary concentrations obtained from seven Cushing's disease patients before and after surgery are shown in Table 2. It can be seen that, after surgery, all cortisol metabolites including cortisol, excluding progesterone, precursors of cortisol, decreased, and the metabolic ratio (F/E) of cortisol to cortisone, indicating the activity of 11β-HSD, increased.
(40) TABLE-US-00002 TABLE 2 Before surgery Immediately after Analyte (pg) surgery (pg) Progesterone 637 ± 118 848 ± 484 20a-hydroxycortisol 842 ± 172 160 ± 39 18-hydroxycortisol 114 ± 46 55 ± 10 Tetrahydrocortisol 4378 ± 442 1911 ± 413 21-deoxycortisol 191 ± 113 178 ± 22 Cortisol (F) 4724 ± 1116 1529 ± 288 Cortisone (E) 3038 ± 337 929 ± 277 F/E 0.63 ± 0.99 1.26 ± 1.24
(41) The present invention provides a method for evaluating adrenal grand function-related metabolic activity by determining metabolic ratios of compounds based on quantitative results of adrenal steroids including cortisol and cortisone measured from a trace amount of saliva collected with cotton swabs. In addition, the use of swabs has the advantages of obtaining samples from normal subjects as well as severe patients through non-invasive and easy sampling, and obtaining constant results, regardless of the amount of sample collected, by measuring the metabolic ratios between the compounds measured from the same sample.
(42) The effects of the present invention are not limited to the effects mentioned above. It should be understood that the effects of the present invention include all reasonably possible effects in the following description.
(43) The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated by those skilled in the art that changes may be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.